Browsing by Author Chio, Adriano

Jump to: 0-9 A B C D E F G H I J K L M N O P Q R S T U V W X Y Z
or enter first few letters:  
Showing results 1 to 4 of 4
Issue DateTitleAuthor(s)Citation
2013Apparent anticipation in SOD1 familial amyotrophic lateral sclerosisNicholson, Garth; Vucic, Steve; Chio, Adriano; Kiernan, Matthew; Concord Clinical School: ANZAC Research Institute; Western Clinical School: Medicine (Westmead)Apparent anticipation in SOD1 familial amyotrophic lateral sclerosis, Amyotrophic Lateral Sclerosis, vol.14, 5, 2013,pp 452-456
2013Controversies and priorities in amyotrophic lateral sclerosisNicholson, Garth; Vucic, Ostoja (Steve); Benatar, Michael; Brooks, Benjamin; Chio, Adriano; de Carvalho, Mamede; et al, Various; Hardiman, Orla; Ince, Paul; Lin, Cindy; Miller, Robert; Mitsumoto, Hiroshi; Turner, Martin R; Concord Clinical School: ANZAC Research Institute; Western Clinical School: Medicine (Westmead)Controversies and priorities in amyotrophic lateral sclerosis, Lancet Neurology, vol.12, 3, 2013,pp 310-322
2012Frequency of the C9orf72 hexanucleotide repeat expansion in patients with amyotrophic lateral sclerosis and frontotemporal dementia: a cross-sectional studyPamphlett, Roger; Abramzon, Yevgeniya; Chio, Adriano; Dopper, Elise; et al, various; Johnson, Janel; Majounie, Elisa; Mok, Kin; Nicolaou, Nayia; Renton, Alan; Restagno, Gabriella; Rollinson, Sara; Sendtner, Michael; Simon-Sanchez, Javier; van Swieten, John; Waite, Adrian; School of Medical Sciences: PathologyFrequency of the C9orf72 hexanucleotide repeat expansion in patients with amyotrophic lateral sclerosis and frontotemporal dementia: a cross-sectional study, The Lancet Neurology, vol.11, 4, 2012,pp 323-330
2017Safety and efficacy of ozanezumab in patients with amyotrophic lateral sclerosis: a randomised, double-blind, placebo-controlled, phase 2 trialKiernan, Matthew; Chio, Adriano; et al, Various; Genge, A; Kim, Seung H; Leigh, P; Ludolph, A; Meininger, Vincent; Robberecht, Wim; Shefner, Jeremy; van den Berg, Leonard; Central Clinical School: MedicineSafety and efficacy of ozanezumab in patients with amyotrophic lateral sclerosis: a randomised, double-blind, placebo-controlled, phase 2 trial, The Lancet Neurology, vol.16, 3, 2017,pp 208-216